Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study

Vaccine

Volumn 33, Issue 38, 2015, Pages 4938-4944

  Mullaert, Jimmy ^a   Abgrall, Sophie ^b,c,d   Lele, Nathalie ^e   Batteux, Frederic ^e,f   Slama, Lilia Ben ^f,g   Meritet, Jean Francois ^f   Lebon, Pierre ^f   Bouchaud, Olivier ^c,d   Grabar, Sophie ^a,b,e   Launay, Odile ^e,f,g  

^a Institut Cochin   (France)

^b INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^c AVICENNE HOSPITAL   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g INSERM   (France)

Author keywords

Diphtheria; Hepatitis B; HIV; Migrants; Poliomyelitis; Tetanus; Vaccination; Yellow fever

Indexed keywords

DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS ANTIBODY; YELLOW FEVER VACCINE;

ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; DIPHTHERIA; FEMALE; FRANCE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MIGRANT; POLIOMYELITIS; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; TETANUS; TRAVEL; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS STRAIN; YELLOW FEVER; COMPLICATION; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; MIGRATION;

ADULT; AFRICA SOUTH OF THE SAHARA; DIPHTHERIA; FEMALE; FRANCE; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLIOMYELITIS; SEROEPIDEMIOLOGIC STUDIES; TETANUS; TRANSIENTS AND MIGRANTS; TRAVEL; YELLOW FEVER;

EID: 84940723198     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.036     Document Type: Article

References (30)

1. 2013 vaccination schedule and recommendations from the "Haut Conseil de la santé publique" in France. BEH 2013; (14-15). Available at: 〈http://www.invs.sante.fr/Publications-et-outils/BEH-Bulletin-epidemiologique-hebdomadaire/Archives/2013/BEH-n-14-15-2013〉.
2. Rubin L.G., Levin M.J., Ljungman P., Davies E.G., Avery R., Tomblyn M., et al. 2013 IDSA Clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis: Off Publ Infect Dis Soc Am 2014, 58(3):309-318. 10.1093/cid/cit816.
3. Adult Immunization Schedules. 2014. Available at: 〈http://www.cdc.gov/vaccines/schedules/hcp/adult.html.〉.
4. Vaccination des personnes immunodéprimées ou aspléniques. 2012. Available at: 〈http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=322.〉.
5. Montlahuc C., Guiguet M., Abgrall S., et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003-2009). J Acquir Immune Defic Syndr 2013, 64(2):197-203. [1999]. 10.1097/QAI.0b013e31829cfbfa.
6. Cazein F., Pinget R., Lot F., et al. New HIV and AIDS diagnoses-France 2003-2011. BEH 2013, 28-29:333-340. http://www.invs.sante.fr/beh/2013/28-29/pdf/2013_28-29.pdf.
7. Dray-Spira R, Wilson d'Almeida K, Aubrière S, et al. Health status of people living with HIV followed at hospital in metropolitan France in 2011 and characteristics of those recently diagnosed, Results of the ANRS-VESPA2 Study, Available at: 〈http://www.invs.sante.fr/beh/2013/27/2013_26-27_1.html, 2013;26-27〉.
8. Pacanowski J., Lacombe K., Campa P., et al. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 2012, 59(4):360-367. [1999]. 10.1097/QAI.0b013e318249de59.
9. Kernéis S., Launay O., Ancelle T., et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res 2013, 65(9):1522-1528. 10.1002/acr.22021.
10. Kernéis S., Launay O., Turbelin C., Batteux F., Hanslik T., Boëlle P.-Y. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis: Off Publ Infect Dis Soc Am 2014, 10.1093/cid/cit937.
11. Barte H., Horvath T.H., Rutherford G.W. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev 2014, 1:CD010929. 10.1002/14651858.CD010929.pub2.
12. Molton J., Smith C., Chaytor S., et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect 2010, 61(1):73-80. 10.1016/j.jinf.2010.04.004.
13. Abgrall S., Fugon L., Lélé N., et al. Visiting one's native country: the risks of nonadherence in HIV-infected sub-Saharan migrants-ANRS VIHVO study. J Int Assoc Provid AIDS Care 2013, 12(6):407-413. 10.1177/2325957413488181.
14. Dömök I, Magrath DI. Guide to Poliovirus isolation and serological techniques for poliomyelitis surveillance. 1979. Available at: 〈http://whqlibdoc.who.int/offset/WHO_OFFSET_46.pdf.〉.
15. Niedrig M., Lademann M., Emmerich P., Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health TM IH 1999, 4(12):867-871.
16. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24(8):1159-1169. 10.1016/j.vaccine.2005.08.105.
17. Zaccaro D.J., Wagener D.K., Whisnant C.C., Staats H.F. Evaluation of vaccine-induced antibody responses: impact of new technologies. Vaccine 2013, 31(25):2756-2761. 10.1016/j.vaccine.2013.03.065.
18. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34(2):272-279.
19. Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection. 2008. Available at: 〈http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5708a1.htm.〉.
20. Hoover K.W., Butler M., Workowski K.A., et al. Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis 2012, 39(5):349-353. 10.1097/OLQ.0b013e318244a923.
21. Pires de Miranda M., Carmo Gomes M., Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal 2002. Euro Surveill: Bull Eur Sur Mal Transm Eur Commun Dis Bull 2007, 12(6):E7-E8.
22. De Melker H.E., van den Hof S., Berbers G.a.M., Conyn-van Spaendonck M.a.E. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003, 21(7-8):716-720.
23. Annunziata K., Rak A., Del Buono H., DiBonaventura M., Krishnarajah G. Vaccination rates among the general adult population and high-risk groups in the United States. PloS One 2012, 7(11):e50553. 10.1371/journal.pone.0050553.
24. Mohseni-Zadeh M., Rey D., Batard M.-L., et al. Inadequate vaccination coverage in a French cohort of HIV positive patients. Méd Mal Infect 2010, 40(12):683-690. 10.1016/j.medmal.2010.06.005.
25. Circulating vaccine-derived poliovirus1; 2014. Available at: 〈http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx.〉.
26. Robinson M.J., Heal C., Gardener E., Powell P., Sims D.G. Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease. Pediatrics 2004, 113(4):733-737.
27. Hochberg N.S., Barnett E.D., Chen L.H., et al. International travel by persons with medical comorbidities: understanding risks and providing advice. Mayo Clin Proc 2013, 88(11):1231-1240. 10.1016/j.mayocp.2013.07.018.
28. WHO|WHO statement on the meeting of the International Health Regulations Emergency Committee concerning the international spread of wild poliovirus, WHO, Available at: 〈http://www.who.int/mediacentre/news/statements/2014/polio-20140505/en/〉; 2014 [accessed 02.09.14].
29. Wallace G.S., Seward J.F., Pallansch M.A. Centers for disease control and prevention. Interim CDC guidance for polio vaccination for travel to and from countries affected by wild poliovirus. MMWR Morb Mortal Wkly Rep 2014, 63(27):591-594.
30. Advice concerning a booster vaccination against poliomyelitis for some travellers in the context of the current public health emergency declared by the WHO, Available at: 〈.〉; 2014. http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20140627_vaccpoliorecovoyageurs_en.pdf.